ASMB Assembly Biosciences Inc

Price (delayed)

$2.08

Market cap

$100.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.77

Enterprise value

$62.77M

Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the ...

Highlights
The company's debt fell by 36% YoY and by 11% QoQ
Assembly Biosciences's revenue has shrunk by 82% YoY
ASMB's gross profit has shrunk by 82% YoY

Key stats

What are the main financial stats of ASMB
Market
Shares outstanding
48.44M
Market cap
$100.75M
Enterprise value
$62.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.81
Price to sales (P/S)
16.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.04
Earnings
Revenue
$6.25M
EBIT
-$129.14M
EBITDA
-$128.66M
Free cash flow
-$83.65M
Per share
EPS
-$2.77
Free cash flow per share
-$1.73
Book value per share
$2.57
Revenue per share
$0.13
TBVPS
$2.97
Balance sheet
Total assets
$143.45M
Total liabilities
$19.47M
Debt
$5.08M
Equity
$123.98M
Working capital
$109.33M
Liquidity
Debt to equity
0.04
Current ratio
8.31
Quick ratio
7.83
Net debt/EBITDA
0.3
Margins
EBITDA margin
-2,057.3%
Gross margin
100%
Net margin
-2,024.5%
Operating margin
-2,070.7%
Efficiency
Return on assets
-67.9%
Return on equity
-76.2%
Return on invested capital
-111.9%
Return on capital employed
-100.5%
Return on sales
-2,065%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ASMB stock price

How has the Assembly Biosciences stock price performed over time
Intraday
-2.35%
1 week
-4.15%
1 month
1.96%
1 year
-41.57%
YTD
-10.73%
QTD
-0.95%

Financial performance

How have Assembly Biosciences's revenue and profit performed over time
Revenue
$6.25M
Gross profit
$6.25M
Operating income
-$129.5M
Net income
-$126.61M
Gross margin
100%
Net margin
-2,024.5%
Assembly Biosciences's revenue has shrunk by 82% YoY
ASMB's gross profit has shrunk by 82% YoY
Assembly Biosciences's operating income has decreased by 37% YoY
Assembly Biosciences's net income has decreased by 35% YoY

Growth

What is Assembly Biosciences's growth rate over time

Valuation

What is Assembly Biosciences stock price valuation
P/E
N/A
P/B
0.81
P/S
16.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.04
ASMB's EPS is down by 14% year-on-year
The price to book (P/B) is 75% lower than the 5-year quarterly average of 3.3 but 19% higher than the last 4 quarters average of 0.7
The equity has decreased by 47% YoY and by 16% from the previous quarter
Assembly Biosciences's revenue has shrunk by 82% YoY
ASMB's price to sales (P/S) is 52% lower than its 5-year quarterly average of 34.2 and 6% lower than its last 4 quarters average of 17.5

Efficiency

How efficient is Assembly Biosciences business performance
The company's return on assets has shrunk by 105% YoY and by 17% QoQ
The return on equity has dropped by 102% year-on-year and by 17% since the previous quarter
The ROIC has plunged by 102% YoY and by 15% from the previous quarter

Dividends

What is ASMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ASMB.

Financial health

How did Assembly Biosciences financials performed over time
ASMB's quick ratio is down by 45% year-on-year and by 32% since the previous quarter
The total assets has contracted by 45% YoY and by 12% from the previous quarter
The company's debt is 96% lower than its equity
The equity has decreased by 47% YoY and by 16% from the previous quarter
The company's debt fell by 36% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.